B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration

Neoplasma

Volumn 54, Issue 6, 2007, Pages 527-535

  Luczynski W ^a   Stasiak Barmuta, A ^a   Piszcz, J ^a   Ilendo E ^a   Kowalczuk, O ^a   Krawczuk Rybak, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

CD40L; Chronic lymphocytic leukemia; Dendritic cells; T lymphocytes

Indexed keywords

CD134 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; HLA DR ANTIGEN; INTERLEUKIN 4; MESSENGER RNA; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE MIGRATION; MALE; T LYMPHOCYTE; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; B CELL LEUKEMIA; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MIXED LYMPHOCYTE CULTURE; NEUTROPHIL CHEMOTAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANTIGEN-PRESENTING CELLS; CD40 LIGAND; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; RECEPTORS, OX40; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 38949112965     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. RAVANDI F, O'BRIEN S Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 197-209. (Pubitemid 41682592)
2. ŁUCZYŃSKI W, STASIAK-BARMUTA A, IŁENDO E, et al. Low expression of costimulatory molecules and mRNA for cytokines are important mechanisms of immunosuppression in acute lymphoblastic leukemia in children ? Neoplasma 2006; 53: 301-304.
3. D'AMICO G, VULCANO M, BUGARIN C, et al. CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12 defective APCs that induce allogeneic T-cell anergy. Blood 2004; 104: 744-751.
4. ŁUCZYŃSKI W, STASIAK-BARMUTA A, IŁENDO E, et al. CD40 stimulation induces differentiation of acute lymphoblastic leukemia cells into dendritic cells. Acta Biochim Pol 2006; 53: 377-382.
5. ROUSSEAU RF, BIAGI E, DUTOUR A, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 2006; 107: 1332-1341.
6. HAINING WN, CARDOSO AA, KECZKEMETHY HL, et al. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol 2005; 33: 286-294.
7. von BERGWELT-BAILDON M, MAECKER B, SCHULTZE J, et al. CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol 2004; 15: 853-857.
8. GHIA P, TRANSDICO P, VEIGA JP, et al. Chemoattractants MDC and TARC are secreted by malignant B-cell presursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 2001; 98: 533-540.
9. MOHTY M, ISNARDON D, CHARBONNIER A, et al. Generation of potent Th1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells. Int Immunol 2002; 14: 741-750.
10. HOOGENDOORN M, WOLBERS JO, SMIT WM, et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia 2004; 18: 1278-1287.
11. MAYR C, KOFLER DM, BUNING H, et al. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood 2005; 106: 3223-3226.
12. PALENA C, FOON KA, PANICALI D, et al. Potential approach to immunotherapy in chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding from multiple costimulatory molecules. Blood 2005; 106: 3515-3523.
13. LEE J, SAIT SN, WETZLER M Characterisation of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts. Int Immunol 2004; 16: 1377-1389.
14. ZHOU T, CHEN Y, HAO L, et al. DC-SIGN and immunoregulation. Cell Mol Immunol 2006; 3: 279-283
15. VERRA N, DE JONG D, BEX A, et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 2005; 48: 527-533.
16. + T cells by producing CCL22. Eur J Immunol 2002; 32: 1403-1413.
17. KIM KD, CHOI SC, NOH YW, et al. Impaired responses of leukemic dendritic cells derived from a human myeloid cell line to LPS-stimulation. Exp Mol Med 2006; 38: 72-84. (Pubitemid 43352436)
18. LEE JM, MERRITT RE, MAHTABIFARD A, et al. Intratumoral expression of macrophage-derived chemokine induced CD4+ T cell-independent antitumor immunity in mice. J Immunother 2003; 26: 117-129.
19. WEIHRAUCH MR, MANZKE O, BEYER M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005; 65: 5516-5519.
20. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
21. BUHMANN R, NOLTE A, WESTHAUS D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999; 93: 1992-2002.
22. + T cells. Immunol Lett 2006; 106: 27-33.
23. BIAGI E, DOTTI G, YVON E, et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B-cells induces expansion of autologous tumor-reactive cytotoxic T-lymphocytes. Blood 2005; 105: 2436-2442.
24. PAZ-MORANTE M, BRIONES J, CANTO E, et al. Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease. Clin Ex Immunol 2006; 145: 36-43.
25. + (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004; 126: 697-703.
26. BIAGI E, ROUSSEAU R, YVON E, et al. Responses to human CD40 ligand/human interleukin-2 autologouscell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 2005; 11 (19 Pt 1): 6916-6923.
27. GRUBER TA, SKELTON DC, KOHN DB Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells. J Immunol 2002; 168: 73-80.
28. SURESH K, FRASER G, SCHEID E, et al. Generation of in vitro B-CLL specific HLA class I restricter CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate. Leuk Lymphoma 2006; 47: 297-306.
29. ROMANO C, DEFANIS U, SELLITTO A, et al. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells. Leuk Lymphoma 2003; 44: 1963-1971.
30. SPANER DE, SHI Y, WHITE D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 286-295.